IU Health, the top-ranked healthcare system in Indiana, has started the first TP-IAT (total pancreatectomy with islet auto-transplant) program in Indiana.
| INDIANAPOLIS, July 29, 2019 /PRNewswire/ -- Indiana University Health and Koligo Therapeutics, Inc. announced the start of the first and only TP-IAT program in Indiana for eligible patients suffering from chronic or recurrent acute pancreatitis. Until now, Indiana patients could only undergo TP-IAT at an out-of-state hospital.
Kathy McGreevy, RN, is the patient navigator for referrals to IU Health. Patients or physicians may contact Ms. McGreevy at 317-948-2676 or kmcgreev@iuhealth.org. Dr. Zyromski notes: “We are excited to be the first program in Indiana to provide TP-IAT. This is an important treatment option for eligible patients with chronic and recurrent acute pancreatitis. This new program aligns with IU Health’s goal to provide patients with leading-edge treatment options and access to medical and surgical specialists that are not available elsewhere in Indiana.” KYSLECEL, produced by Koligo Therapeutics, is intended to preserve insulin secretory capacity in TP-IAT patients. An IU Health surgeon resects (removes) the pancreas and sends it to Koligo’s FDA-registered facility. Koligo isolates pancreatic islets to make KYSLECEL which is then re-infused into the liver, where the islets are intended to engraft and produce insulin. TP-IAT is a major surgery that carries significant risks and potential benefits. Patients should discuss treatment options with a healthcare professional. More information about TP-IAT and KYSLECEL is available at www.koligo.net. About IU Health Media Contact
SOURCE Koligo Therapeutics, Inc. |
View original content to download multimedia:
